Combined therapy in children and adolescents with classical Hodgkin's lymphoma: A report from the SFCE on MDH-03 national guidelines

References

• Gerres L, Bramswig JH, Schlegel W, Jurgens H, Schellong G. The effects of etoposide on testicular function in boys treated for Hodgkin's disease. Cancer. 1998;83(10):2217–2222.
   PubMed Web of Science ®Google Scholar
• Schellong G, Hornig-Franz I, Rath B, et al. [Reducing radiation dosage to 20–30 Gy in combined chemo-/radiotherapy of Hodgkin's disease in childhood. A report of the cooperative DAL-HD-87 therapy study]. Klin Padiatr. 1994;206(4):253–262.
   PubMed Web of Science ®Google Scholar
• Hudson MM, Greenwald C, Thompson E, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol. 1993;11(1):100–108.
   PubMed Web of Science ®Google Scholar
• Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol. 2004;22(22):4541–4550.
   PubMed Web of Science ®Google Scholar
• Schellong G, Oberlin O, Vecchi V, et al. Stage IV Hodgkin's disease in children: Combined modality treatment involving OPPA/COPP chemotherapy—A European study in the International Society of Pediatric Oncology. Leuk Lymphoma. 1998;29:100.
   Google Scholar
• Oberlin O. Present and future strategies of treatment in childhood Hodgkin's lymphomas. Ann Oncol. 1996;7 Suppl 4:73–78.
   PubMedGoogle Scholar
• Kelly KM. Hodgkin lymphoma in children and adolescents: improving the therapeutic index. Blood. 2015;126(22):2452–2458.
   PubMed Web of Science ®Google Scholar
• Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol. 2000;18(7):1500–1507.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835–3849.
   PubMed Web of Science ®Google Scholar
• Ferme C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol. 1995;6(6):543–549.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008;26(36):5980–5987.
   PubMed Web of Science ®Google Scholar
• Gorde-Grosjean S, Oberlin O, Leblanc T, et al. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Societe Francaise de Lutte contre le Cancer des Enfants et des Adolescents (SFCE). Br J Haematol. 2012;158(5):649–656.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
   PubMed Web of Science ®Google Scholar
• Lacour B, Guyot-Goubin A, Guissou S, Bellec S, Desandes E, Clavel J. Incidence of childhood cancer in France: National Children Cancer Registries, 2000–2004. Eur J Cancer Prev. 2010;19(3):173–181.
   PubMed Web of Science ®Google Scholar
• Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051–2059.
   PubMed Web of Science ®Google Scholar
• Mauz-Korholz C, Hasenclever D, Dorffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010;28(23):3680–3686.
   PubMed Web of Science ®Google Scholar
• Tebbi CK, Mendenhall NP, London WB, et al. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012;59(7):1259–1265.
   PubMed Web of Science ®Google Scholar
• Farruggia P, Puccio G, Sala A, et al. The prognostic value of biological markers in paediatric Hodgkin lymphoma. Eur J Cancer. 2016;52:33–40.
   PubMed Web of Science ®Google Scholar
• Oberlin O, Leverger G, Pacquement H, et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol. 1992;10(10):1602–1608.
   PubMed Web of Science ®Google Scholar
• Glick JH, Young ML, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998;16(1):19–26.
   PubMed Web of Science ®Google Scholar
• Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol. 2007;25(3):332–337.
   PubMed Web of Science ®Google Scholar
• Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117(6):1806–1816.
   PubMed Web of Science ®Google Scholar
• van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012;30(13):1429–1437.
   PubMed Web of Science ®Google Scholar
• Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55(6):1145–1152.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334(12):745–751.
   PubMed Web of Science ®Google Scholar
• Pellegrino B, Oberlin O, Leblanc T, et al. 2MOPP and 2 ABVP followed by low dose RT for Stage III children Hodgkin lymphoma. Ann Oncol. 2002;13(Suppl 2):29–32.
   PubMedGoogle Scholar
• Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014;32(32):3651–3658.
   PubMed Web of Science ®Google Scholar
• Oberlin O, Pacquement H, et al. for the SIOP Hogkin study group. Stages IV Hodgkin's disease: results of the study of the International Society of Paediatric Oncology. 1993:71.
   Google Scholar
• Ruhl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys. 2001;51(5):1209–1218.
   PubMed Web of Science ®Google Scholar
• Moskowitz CS, Chou JF, Wolden SL, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32(21):2217–2223.
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015;373(26):2499–2511.
   PubMed Web of Science ®Google Scholar
• Kelly KM. Management of children with high-risk Hodgkin lymphoma. Br J Haematol. 2012;157(1):3–13.
   PubMed Web of Science ®Google Scholar
• Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol. 1999;17(12):3736–3744.
   PubMed Web of Science ®Google Scholar